Evonik's Takeover Math Meets Its Product Pipeline as November Looms

Evonik finds itself pulled in two directions at once. On one side sits a possible takeover by BASF whose outcome rests largely in the hands of a single major shareholder. On the other, a steady stream of product launches and partnerships is quietly building the case for the specialty chemicals maker as a standalone business. For investors, the trick is keeping the two stories apart.

The pivotal player in any deal is the RAG-Stiftung, which holds 44% of Evonik's shares according to Handelsblatt. Its board of trustees met on 9 October and declined to take a position on BASF's offer, pointing instead to bilateral talks between the two companies. That silence is neither a green light nor a veto — a distinction that matters enormously for anyone weighing the takeover angle.

A Major Holder Keeps Its Cards Close

Whether the foundation would back a sale of its Evonik stake is the question that carries the most weight. A supportive stance could strengthen the odds of an agreement; outright opposition would dent expectations of any deal getting done. Neither scenario has materialized as an actual decision.

The skepticism isn't confined to the boardroom. IG BCE chief Michael Vassiliadis and Alexander Bercht raised doubts about a full sale in a letter to works councils at both BASF and Evonik, warning against rushing things in a 9 October communication. The debate, then, isn't purely about price — it also touches on whether the stake should change hands at all, and in what form.

Where the Numbers Stand

BASF has reportedly signaled a willingness to discuss a higher offer once it gains access to Evonik's books. Evonik rejected the initial bid of EUR 22.15 per share as too low, according to dpa-AFX sources. That openness to a sweetened bid is a financial incentive, but it is not proof that the key parties would support a sale.

Should the two sides move closer while the RAG-Stiftung backs a disposal, the setup would look considerably more solid. Progress in talks and a constructive stance from the foundation could turn the possibility of a higher bid into something more durable. A revised offer, though, is not guaranteed. Nor would employment concerns necessarily sharpen in such a scenario: dpa-AFX sources indicate BASF would fully honor existing employment and site agreements in the event of a takeover — commitments that could soften objections without substituting for either shareholder approval or a meeting of minds on price.

Political Friction Adds a Layer

The counterweight comes from Düsseldorf. North Rhine-Westphalia's economy minister, Mona Neubaur, spoke out against a BASF takeover of Evonik in the state parliament on 14 October, Handelsblatt reported. At the same time, the Landtag rejected an SPD motion calling for stronger state intervention. The political opposition therefore signals neither a confirmed entry by the state nor a fait accompli of failure — but it does add another set of interests to weigh alongside the offer price.

One trap for investors would be reading BASF's willingness to talk about a higher bid as an announcement that one is coming. That openness is tied to seeing Evonik's books. If talks stall or the foundation comes out against a sale, the takeover scenario loses traction, and the standalone business would have to carry more of the valuation.

Meanwhile, the Pipeline Keeps Moving

Against that backdrop, Evonik has been busy on the operational front. This week it introduced the VESTAKEEP PEEK grades DC4760 and DC4780 for long-term dental prosthetics. It also launched Lypron, a rumen-protected lysine solution for ruminants. For Lypron, the company paired the market launch with a clear division of labor: France's Sipena co-developed the solution and will manufacture it exclusively for Evonik — an arrangement covering not just development but future production.

Add to that a recycling initiative agreed roughly a week earlier in Japan. Evonik is working with Toyotsu Chemiplas Corporation and Sanyo Chemical Industries to develop a recycling model for polyurethane foam, contributing its hydrolysis recycling technology. These are concrete product and cooperation activities, though no quantified earnings contribution can be derived from them yet. They belong to the operational picture, not to a demonstrated improvement in profitability.

Two Tests Running in Parallel

The next hard date is 3 November 2026, when Evonik publishes its Q3 2026 results. That release will be the occasion to judge the standalone business — the dental materials and the Lypron launch form the operational backdrop, but the product announcements do not substantiate any specific earnings contribution.

A separate dispute is also simmering. Vassiliadis, in an interview reported by Handelsblatt on 16 October, referred to "problematic financing issues" at Evonik. The company rejected any suggestion of financing problems and pointed to improved credit ratings. Those two positions sit side by side: a union leader's critical remark and an explicit denial from the company. The comment cannot be presented as a confirmed funding squeeze, just as the ratings reference is Evonik's own justification for its rebuttal. Operational progress does not settle questions about the balance sheet, and a critical interview does not overturn the company's account.

So investors face two separate checks. First, does the prospect of a workable takeover agreement improve — and there the RAG-Stiftung's position remains central. Second, how does Evonik perform on its own merits — and the quarterly figures due in November will provide the next concrete pointer.